- Q3 2023 Astria Therapeutics Inc Earnings Call TranscriptNov 13, 2023$4.49 (-2.39%)Earnings
- Astria Therapeutics Inc to Discuss the OX40 Program STAR-0310 Call TranscriptOct 12, 2023
- Astria Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q4 2022 Astria Therapeutics Inc Earnings Call TranscriptMar 22, 2023$11.33 (+0.98%)Earnings
- Astria Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Astria Therapeutics Inc Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 TranscriptDec 15, 2022
- Astria Therapeutics Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Astria Therapeutics Inc R&D Day: Update On STAR-0215 And Its Clinical Development For The Prevention Of HAE Attacks TranscriptSep 30, 2022
- Q3 2021 Astria Therapeutics Inc Earnings Call TranscriptNov 10, 2021$7.07 (+0.86%)Earnings
- Catabasis Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 13, 2021
- Catabasis Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 02, 2021
- Catabasis Pharmaceuticals Inc Acquisition of Quellis Biosciences Inc Call TranscriptJan 29, 2021
- Catabasis Pharmaceuticals, Inc. - Special Call TranscriptSep 11, 2020
- Q4 2019 Catabasis Pharmaceuticals Inc Earnings Call TranscriptMar 10, 2020$28.74 (+1.91%)Earnings
- Q3 2019 Catabasis Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2019$31.74 (+1.93%)Earnings
- Q2 2019 Catabasis Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2019$39.66 (+1.85%)Earnings
- Q1 2019 Catabasis Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2019$47.46 (+4.91%)Earnings
- Q4 2018 Catabasis Pharmaceuticals Inc Earnings Call TranscriptMar 14, 2019$34.8 (+3.57%)Earnings
Q2 2019 Catabasis Pharmaceuticals Inc Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Q2 2019 Catabasis Pharmaceuticals, Inc. Earnings Conference Call. (Operator Instructions)
I would now like to turn the call over to Andrea Matthews, Vice President, Corporate Affairs. Ma'am, you may begin.
Thank you, Sydney. Welcome to today's Catabasis Pharmaceuticals conference call where we will provide a corporate update and review our second quarter 2019 financial results. With me today are Jill Milne, Chief Executive Officer; Joanne Donovan, Chief Medical Officer; Andrew Nichols, Chief Scientific Officer; and Noah Clauser, Vice President of Finance.
We issued a press release this morning summarizing our corporate update and our Q2 2019 financial results, which we will reference on today's call and is available on our website. We are also using slides during today's call that are available within the Events and Presentations section in the investors part of our website.
I would like to note that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)